Shots:

• J&J has resumed recruitment- enrolment- and vaccination in all studies of its COVID-19 vaccine across the EU- after a temporary pause. Trials in the US- South Africa- and some Latin American countries are already ongoing
• Clinical trials to be resumed are the P-IIa studies in Germany- the Netherlands- and Spain and P-I/IIa study in Belgium
• The company is preparing for the initiation of a second P-III study of the COVID-19 vaccine candidate. The trial will evaluate a 2-dose regimen and is anticipated to start later this month across the EU. The study follows positive interim results of the P-I/IIa study- showing the safety profile and immunogenicity of the COVID-19 vaccine was supportive of further development

 ­ Ref: Janssen | Image: Law.com